ERBB2 and breast carcinoma: For instance, in a randomized phase III clinical trial called PALOMA-3, including 521 patients with HR-positive HER2-negative breast cancer randomly assigned to receive either palbociclib with fulvestrant or placebo with fulvestrant, the median overall survival (OS) improved by 6.9 months in the palbociclib arm versus the control arm, at a median follow-up duration of 44.8 months (HR, 0.81; 95% CI, 0.64 to 1.03, p = 0.09) [54].